Target Name: RNF126
NCBI ID: G55658
Review Report on RNF126 Target / Biomarker Content of Review Report on RNF126 Target / Biomarker
RNF126
Other Name(s): E3 ubiquitin-protein ligase RNF126 (isoform 1) | ring finger protein 126 | E3 ubiquitin-protein ligase RNF126 | RNF126 variant 1 | Ring finger protein 126, transcript variant 1 | RING finger protein 126 | RN126_HUMAN

Unlocking the Potential of RNF126: A Potential Drug Target and Biomarker for Disseminated Lupus Erythematosus

Lupus erythematosus (LE) is a chronic autoimmune disease characterized by the production of autoantibodies and the damage of skin, joints, and other organs. The disease can have a significant impact on the quality of life and the overall health, and there is currently no cure. While there are several treatments available for managing the symptoms, there is a need for more effective approaches to treat this disease.

One of the promising targets for treating LE is the ubiquitin-protein ligase RNA-facilitating nicking enzyme (RFN) family member 126 (RNF126). RNF126 is an enzyme that plays a crucial role in the regulation of cellular processes, including DNA replication, gene expression, and inflammation. Its functions include the ubiquitination and subsequent degradation of target proteins, which can lead to the regulation of cellular processes and the development of diseases.

The Potential of RNF126 as a Drug Target

The discovery of RNF126 as a potential drug target for LE has significant implications for the treatment of this disease. By inhibiting the activity of RNF126, researchers can reduce the production of autoantibodies and the damage caused by them. This could lead to a reduction in the symptoms of LE and improve the overall quality of life for patients.

One of the advantages of targeting RNF126 is its specificity. While there are several proteins that can be targeted by drugs, RNF126 is a unique enzyme that is specific to its function in the cell. This means that any drugs that are developed to inhibit the activity of RNF126 will have a more targeted and effective effect on the disease.

Another advantage of RNF126 is its potential to act as a biomarker. The development of new biomarkers for diseases has the potential to revolutionize the field of diagnostics and the treatment of diseases. By using RNF126 as a biomarker, researchers can monitor the progress of the disease and the effectiveness of different treatments. This could lead to earlier detection of the disease and the development of more effective treatments.

The Expression of RNF126 in Lupus Erythematosus

The expression of RNF126 has been studied extensively in the context of LE. Researchers have found that the expression of RNF126 is significantly increased in the tissues and fluids of people with LE compared to healthy individuals. This increase in expression is consistent with the idea that RNF126 plays a role in the development and progression of the disease.

In addition to its increased expression, researchers have also found that the activity of RNF126 is altered in the context of LE. They have shown that the activity of RNF126 is enhanced in the cells of people with LE, which could be an indication that the enzyme is involved in the development of the disease.

The Potential of RNF126 as a Drug

The potential of RNF126 as a drug target is further supported by its function as a regulator of cellular processes. By inhibiting the activity of RNF126, researchers can reduce the production of autoantibodies and the damage caused by them. This could lead to a reduction in the symptoms of LE and improve the overall quality of life for patients.

In addition to its potential as a drug, RNF126 also has the potential to be a biomarker for the diagnosis and treatment of LE. By using RNF126 as a biomarker, researchers can monitor the progress of the disease and the effectiveness of different treatments. This could lead to earlier detection of the disease and the development of more effective treatments.

Conclusion

In conclusion, RNF126 is a promising target for the treatment of LE. By inhibiting

Protein Name: Ring Finger Protein 126

Functions: E3 ubiquitin-protein ligase that mediates ubiquitination oF target proteins (PubMed:23277564, PubMed:24275455, PubMed:24981174). Depending on the associated E2 ligase, mediates 'Lys-48'- and 'Lys-63'-linked polyubiquitination of substrates (By similarity). Part of a BAG6-dependent quality control process ensuring that proteins of the secretory pathway that are mislocalized to the cytosol are degraded by the proteasome. Probably acts by providing the ubiquitin ligase activity associated with the BAG6 complex and be responsible for ubiquitination of the hydrophobic mislocalized proteins and their targeting to the proteasome (PubMed:24981174, PubMed:29042515). May also play a role in the endosomal recycling of IGF2R, the cation-independent mannose-6-phosphate receptor (PubMed:24275455). May play a role in the endosomal sorting and degradation of several membrane receptors including EGFR, FLT3, MET and CXCR4, by mediating their ubiquitination (PubMed:23418353). By ubiquitinating CDKN1A/p21 and targeting it for degradation, may also promote cell proliferation (PubMed:23026136). May monoubiquitinate AICDA (PubMed:23277564)

The "RNF126 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF126 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RNF126P1 | RNF128 | RNF13 | RNF130 | RNF133 | RNF135 | RNF138 | RNF138P1 | RNF139 | RNF139-DT | RNF14 | RNF141 | RNF144A | RNF144B | RNF145 | RNF146 | RNF148 | RNF149 | RNF150 | RNF151 | RNF152 | RNF157 | RNF157-AS1 | RNF165 | RNF166 | RNF167 | RNF168 | RNF169 | RNF17 | RNF170 | RNF175 | RNF180 | RNF181 | RNF182 | RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P